199 related articles for article (PubMed ID: 26107212)
21. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004.
Kamps WA; van der Pal-de Bruin KM; Veerman AJ; Fiocco M; Bierings M; Pieters R
Leukemia; 2010 Feb; 24(2):309-19. PubMed ID: 20016528
[TBL] [Abstract][Full Text] [Related]
22. HiC-COM: a 2-month intensive chemotherapy regimen for children with stage III and IV Burkitt's lymphoma and B-cell acute lymphoblastic leukemia.
Schwenn MR; Blattner SR; Lynch E; Weinstein HJ
J Clin Oncol; 1991 Jan; 9(1):133-8. PubMed ID: 1985162
[TBL] [Abstract][Full Text] [Related]
23. Improved outcome of acute lymphoblastic leukaemia treated by delayed intensification in Hong Kong children: HKALL97 study.
Li CK; Chik KW; Ha SY; Lee AC; Yuen HL; Ling SC; Lee V; Chan GC; Shing MM; Chan LC; Ng MH
Hong Kong Med J; 2006 Feb; 12(1):33-9. PubMed ID: 16495587
[TBL] [Abstract][Full Text] [Related]
24. Survival Outcome of Filipino Children With Acute Lymphoblastic Leukemia Treated With Modified Berlin-Frankfurt-Muenster/Hong Kong Acute Lymphoblastic Leukemia (BFM95/HKALL97) Protocol in a Tertiary General Hospital From January 2005 to December 2009: A Retrospective Cohort Study.
Dujua AC; Hernandez FG
J Pediatr Hematol Oncol; 2017 Apr; 39(3):e116-e123. PubMed ID: 28085747
[TBL] [Abstract][Full Text] [Related]
25. Poorer outcome of childhood acute lymphoblastic leukemia in the Bedouin population: A report from the Berlin-Frankfurt-Muenster-based Israeli national protocols.
Elhasid R; Nirel R; Avigad S; Avrahami G; Abramov A; Attias D; Arad N; Ballin A; Ben-Arush M; Bielorai B; Burstein Y; Elitzur S; Gabriel H; Hameiri-Grossman M; Kapelushnik J; Sthoeger D; Toren A; Wientraub M; Yaniv I; Izraeli S; Stark B
Pediatr Blood Cancer; 2020 Jan; 67(1):e28024. PubMed ID: 31595664
[TBL] [Abstract][Full Text] [Related]
26. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of therapeutic effectiveness of Nanfang ALL 99 protocol in childhood acute lymphoblastic leukemia patients].
Wu XD; Li CF; He YL; Yang M; Zhang YM; Feng XQ; Teng ZL; Sun SM; Qian XH
Zhonghua Er Ke Za Zhi; 2005 Dec; 43(12):890-3. PubMed ID: 16412348
[TBL] [Abstract][Full Text] [Related]
28. Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America.
Jaime-Pérez JC; Jiménez-Castillo RA; Pinzón-Uresti MA; Cantú-Rodríguez OG; Herrera-Garza JL; Marfil-Rivera LJ; Gómez-Almaguer D
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27957789
[TBL] [Abstract][Full Text] [Related]
29. Absolute Lymphocyte Count Recovery Independently Predicts Outcome in Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Care Cancer Center of a Developing Country.
Gupta A; Kapoor G; Jain S; Bajpai R
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e143-9. PubMed ID: 26201035
[TBL] [Abstract][Full Text] [Related]
30. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
Lu XT
Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
[TBL] [Abstract][Full Text] [Related]
31. [Therapeutic effectiveness of CCLG-97 protocol on standard-risk childhood acute lymphoblastic leukemia].
Xiao PF; Chai YH; Li JQ; He HL; Wang Y; Li ZP; He YX; Ji ZH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):486-9. PubMed ID: 16083544
[TBL] [Abstract][Full Text] [Related]
32. Management of Ontario children with acute lymphoblastic leukemia by the Dana-Farber Cancer Institute protocols.
Desai SJ; Barr RD; Andrew M; deVeber LL; Pai MK
CMAJ; 1989 Oct; 141(7):693-7. PubMed ID: 2790605
[TBL] [Abstract][Full Text] [Related]
33. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
34. No benefit of Interfant protocols compared to BFM-based protocols for infants with acute lymphoblastic leukemia. Results from an institution in Argentina.
Pennella CL; Deu MA; Rossi JG; Baialardo EM; Alonso CN; Rubio P; Guitter MR; La Rosa CGS; Alfaro EM; Zubizarreta PA; Felice MS
Pediatr Blood Cancer; 2020 Oct; 67(10):e28624. PubMed ID: 32729239
[TBL] [Abstract][Full Text] [Related]
35. Ten-year survival of children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Trigg ME; Sather HN; Reaman GH; Tubergen DG; Steinherz PG; Gaynon PS; Uckun FM; Hammond GD;
Leuk Lymphoma; 2008 Jun; 49(6):1142-54. PubMed ID: 18569638
[TBL] [Abstract][Full Text] [Related]
36. A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays.
Suarez A; Piña M; Nichols-Vinueza DX; Lopera J; Rengifo L; Mesa M; Cardenas M; Morrissey L; Veintemilla G; Vizcaino M; Del Toro L; Vicuna V; Fernandez J; Neuberg D; Stevenson K; Gutierrez A
Pediatr Blood Cancer; 2015 Aug; 62(8):1395-402. PubMed ID: 25808195
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia.
Conter V; Aricò M; Basso G; Biondi A; Barisone E; Messina C; Parasole R; De Rossi G; Locatelli F; Pession A; Santoro N; Micalizzi C; Citterio M; Rizzari C; Silvestri D; Rondelli R; Lo Nigro L; Ziino O; Testi AM; Masera G; Valsecchi MG;
Leukemia; 2010 Feb; 24(2):255-64. PubMed ID: 20016536
[TBL] [Abstract][Full Text] [Related]
39. [Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia].
Tang JY; Xue HL; Gu LJ; Chen J; Pan C; Chen J; Wang YP; Ye H; Dong L; Zou JY
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):490-3. PubMed ID: 16083545
[TBL] [Abstract][Full Text] [Related]
40. Poor treatment compliance in children with down syndrome and acute lymphoblastic leukemia.
Bohnstedt C; Taskinen M; Zeller B; Björgvinsdóttir H; Hafsteinsdottir S; Schmiegelow K
J Pediatr Hematol Oncol; 2009 Jan; 31(1):79-80. PubMed ID: 19125098
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
